Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists.
NSCLC
molecular characterization
non-small cell lung cancer
preanalytical
predictive biomarkers
specimen handling
tissue management
tissue stewardship
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
13 Nov 2023
13 Nov 2023
Historique:
revised:
05
10
2023
received:
12
04
2023
accepted:
07
10
2023
medline:
14
11
2023
pubmed:
14
11
2023
entrez:
13
11
2023
Statut:
aheadofprint
Résumé
Many patients with non-small cell lung cancer do not receive guideline-recommended, biomarker-directed therapy, despite the potential for improved clinical outcomes. Access to timely, accurate, and comprehensive molecular profiling, including targetable protein overexpression, is essential to allow fully informed treatment decisions to be taken. In turn, this requires optimal tissue management to protect and maximize the use of this precious finite resource. Here, a group of leading thoracic pathologists recommend factors to consider for optimal tissue management. Starting from when lung cancer is first suspected, keeping predictive biomarker testing in the front of the mind should drive the development of practices and procedures that conserve tissue appropriately to support molecular characterization and treatment selection.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : AstraZeneca
Informations de copyright
© 2023 The Authors. Histopathology published by John Wiley & Sons Ltd.
Références
Howlader N, Forjaz G, Mooradian MJ et al. The effect of advances in lung-cancer treatment on population mortality. N. Engl. J. Med. 2020; 383; 640-649.
Pastorino U, Silva M, Sestini S et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann. Oncol. 2019; 30; 1162-1169.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 2022; 72; 7-33.
Smeltzer MP, Wynes MW, Lantuejoul S et al. The International Association for the Study of Lung Cancer global survey on molecular testing in lung cancer. J. Thorac. Oncol. 2020; 15; 1434-1448.
Kris MG, Johnson BE, Berry LD et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311; 1998-2006.
Aggarwal C, Marmarelis ME, Hwang W-T et al. Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer. 2022 ASCO Annual Meeting Abstract. J. Clin. Oncol. 2022; 40; 9022.
Yatabe Y, Dacic S, Borczuk AC et al. Best practices recommendations for diagnostic immunohistochemistry in lung cancer. J. Thorac. Oncol. 2019; 14; 377-407.
Planchard D, Popat S, Kerr K et al. ESMO clinical practice living guidelines-metastatic non-small-cell lung cancer. 2022 Updated 7 July 2022. Available at https://www.esmo.org/guidelines/guidelines-by-topic/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer/.
Lindeman NI, Cagle PT, Aisner DL et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch. Pathol. Lab. Med. 2018; 142; 321-346.
Hanna NH, Robinson AG, Temin S et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J. Clin. Oncol. 2021; 39; 1040-1091.
Kalemkerian GP, Narula N, Kennedy EB et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J. Clin. Oncol. 2018; 36; 911-919.
Aisner DL, Akerley W, Bauman JR et al. NCCN guidelines version 5.2022. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Updated 7 July 2022. Available at https://www.nccn.org/.
Angerilli V, Galuppini F, Pagni F, Fusco N, Malapelle U, Fassan M. The role of the pathologist in the next-generation era of tumor molecular characterization. Diagnostics 2021; 11; 339.
Ascierto PA, Bifulco C, Palmieri G, Peters S, Sidiropoulos N. Preanalytic variables and tissue stewardship for reliable next-generation sequencing (NGS) clinical analysis. J. Mol. Diagn 2019; 21; 756-767.
Cree IA, Booton R, Cane P et al. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology 2016; 69; 177-186.
Cree IA, Cree IA, Deans Z et al. Guidance for laboratories performing molecular pathology for cancer patients. J. Clin. Pathol. 2014; 67; 923-931.
Roy-Chowdhuri S, Dacic S, Ghofrani M et al. Collection and handling of thoracic small biopsy and cytology specimens for ancillary studies: Guideline from the College of American Pathologists in Collaboration with the American College of Chest Physicians, Association for Molecular Pathology, America. Arch. Pathol. Lab. Med. 2020; 144; 933-958.
Jain D, Allen TC, Aisner DL et al. Rapid on-site evaluation of endobronchial ultrasound-guided transbronchial needle aspirations for the diagnosis of lung cancer: a perspective from members of the pulmonary pathology society. Arch. Pathol. Lab. Med. 2018; 142; 253-262.
Trisolini R, Cancellieri A, Tinelli C et al. Rapid on-site evaluation of transbronchial aspirates in the diagnosis of hilar and mediastinal adenopathy: a randomized trial. Chest 2011; 139; 395-401.
Chandan VS, Zimmerman K, Baker P, Scalzetti E, Khurana KK. Usefulness of core roll preparations in immediate assessment of neoplastic lung lesions: comparison to conventional CT scan-guided lung fine-needle aspiration cytology. Chest 2004; 126; 739-743.
Shikano K, Ishiwata T, Saegusa F et al. Feasibility and accuracy of rapid on-site evaluation of touch imprint cytology during transbronchial biopsy. J. Thorac. Dis. 2020; 12; 3057-3064.
Kubik MJ, Bovbel A, Goli H, Saremian J, Siddiqi A, Masood S. Diagnostic value and accuracy of imprint cytology evaluation during image-guided core needle biopsies: review of our experience at a large academic center. Diagn. Cytopathol. 2015; 43; 773-779.
Penault-Llorca F, Kerr KM, Garrido P et al. Expert opinion on NSCLC small specimen biomarker testing-part 1: tissue collection and management. Virchows Arch. 2022; 481; 335-350.
Bass BP, Engel KB, Greytak SR, Moore HM. A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen? Arch. Pathol. Lab. Med. 2014; 138; 1520-1530.
Compton CC, Robb JA, Anderson MW et al. Preanalytics and precision pathology: pathology practices to ensure molecular integrity of cancer patient biospecimens for precision medicine. Arch. Pathol. Lab. Med. 2019; 143; 1346-1363.
Dietel M, Bubendorf L, Dingemans A-MC et al. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax 2016; 71; 177-184.
Bussolati G, Annaratone L, Medico E, D'Armento G, Sapino A. Formalin fixation at low temperature better preserves nucleic acid integrity. PLoS One 2011; 6; e21043.
Berrino E, Annaratone L, Miglio U et al. Cold formalin fixation guarantees DNA integrity in formalin fixed paraffin embedded tissues: premises for a better quality of diagnostic and experimental pathology with a specific impact on breast cancer. Front. Oncol. 2020; 10; 173.
Rolls G. Leica biosystems. [Internet]. Steps to tissue processing for histopathology. Updated 7 July 2022. Available at https://www.leicabiosystems.com/en-gb/knowledge-pathway/an-introduction-to-specimen-processing/.
Confavreux CB, Girard N, Pialat J-B et al. Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC). Bonekey Rep. 2014; 3; 580.
Alers JC, Krijtenburg PJ, Vissers KJ, Van Dekken H. Effect of bone decalcification procedures on DNA in situ hybridization and comparative genomic hybridization. EDTA is highly preferable to a routinely used acid decalcifier. J. Histochem. Cytochem. 1999; 47; 703-709.
Singh VM, Salunga RC, Huang VJ et al. Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. Ann. Diagn. Pathol. 2013; 17; 322-326.
Aisner DL, Rumery MD, Merrick DT et al. Do more with less: tips and techniques for maximizing small biopsy and cytology specimens for molecular and ancillary testing: the University of Colorado Experience. Arch. Pathol. Lab. Med. 2016; 140; 1206-1220.
Padmanabhan V, Steinmetz HB, Rizzo EJ et al. Improving adequacy of small biopsy and fine-needle aspiration specimens for molecular testing by next-generation sequencing in patients with lung cancer: a quality improvement study at Dartmouth-Hitchcock Medical Center. Arch. Pathol. Lab. Med. 2017; 141; 402-409.
Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J. Thorac. Oncol. 2010; 5; 442-447.
Thunnissen E, Boers E, Heideman DAM et al. Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma. Virchows Arch. 2012; 461; 629-638.
Edwards SL, Roberts C, McKean ME, Cockburn JS, Jeffrey RR, Kerr KM. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J. Clin. Pathol. 2000; 53; 537-540.
Cane P, Linklater KM, Nicholson AG, Peake MD, Gosney J. Morphological and genetic classification of lung cancer: variation in practice and implications for tailored treatment. Histopathology 2015; 67; 216-224.
Devereaux KA, Souers RJ, Graham RP et al. Neoplastic cellularity assessment in molecular testing. Arch. Pathol. Lab. Med. 2022; 146; 1062-1071.
Smits AJJ, Kummer JA, De Bruin PC et al. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate. Mod. Pathol. 2014; 27; 168-174.
Teixidó C, Vilariño N, Reyes R, Reguart N. PD-L1 expression testing in non-small cell lung cancer. Ther. Adv. Med. Oncol. 2018; 10; 1758835918763493.
Martin V, Bernasconi B, Merlo E et al. ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice. J. Thorac. Oncol. 2015; 10; 595-602.
Walsh EM, Halushka MK. A comparison of tissue dissection techniques for diagnostic, prognostic, and theragnostic analysis of human disease. Pathobiology 2023; 90; 199-208.
Roy-Chowdhuri S, Stewart J. Preanalytic variables in cytology: lessons learned from next-generation sequencing-The MD Anderson Experience. Arch. Pathol. Lab. Med. 2016; 140; 1191-1199.
Ionescu DN, Stockley TL, Banerji S et al. Consensus recommendations to optimize testing for new targetable alterations in non-small cell lung cancer. Curr. Oncol. 2022; 29; 4981-4997.
Popat S, Navani N, Kerr KM et al. Navigating diagnostic and treatment decisions in non-small cell lung cancer: expert commentary on the multidisciplinary team approach. Oncologist 2021; 26; e306-e315.
Russo A, Incorvaia L, Capoluongo E et al. The challenge of the molecular tumor board empowerment in clinical oncology practice: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. Crit. Rev. Oncol. Hematol. 2022; 169; 103567.
Guirado M, Sanchez-Hernandez A, Pijuan L, Teixido C, Gómez-Caamaño A, Cilleruelo-Ramos Á. Quality indicators and excellence requirements for a multidisciplinary lung cancer tumor board by the Spanish Lung Cancer Group. Clin. Transl. Oncol. 2022; 24; 446-459.
Wang S, Yu B, Ng CC et al. The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer. Transl. Lung Cancer Res. 2015; 4; 119-125.
Young K, da Cunha SG, Card P, Leighl N. The role of cytology in molecular testing and personalized medicine in lung cancer: a clinical perspective. Cancer Cytopathol. 2019; 127; 72-78.
Gupta N, Sekar A, Rajwanshi A. Role of FNAC, fluid specimens, and cell blocks for cytological diagnosis of lung cancer in the present era. J. Cytol. 2015; 32; 217-222.
Tejerina E, García Tobar L, Echeveste JI, de Andrea CE, Vigliar E, Lozano MD. PD-L1 in cytological samples: a review and a practical approach. Front. Med. 2021; 8; 668612.
Bonney A, Christie M, Beaty A et al. The feasibility of molecular testing on cell blocks created from brush tip washings in the assessment of peripheral lung lesions. J. Thorac. Dis. 2016; 8; 2551-2555.
Heymann J, Bulman W, Maxfield R et al. Molecular testing guidelines for lung adenocarcinoma: utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples. Cytojournal 2014; 11; 12.
Tian SK, Killian JK, Rekhtman N et al. Optimizing workflows and processing of cytologic samples for comprehensive analysis by next-generation sequencing: Memorial Sloan Kettering Cancer Center Experience. Arch. Pathol. Lab. Med. 2016; 140; 1200-1205.
World Health Organization. Thoracic tumours-WHO classification of tumours. 5th ed, Volume 5. Lyon, France: WHO Classification of Tumours Editorial Board, 2021.
Aggarwal C, Thompson JC, Black TA et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2019; 5; 173-180.
Leighl NB, Page RD, Raymond VM et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin. Cancer Res. 2019; 25; 4691-4700.
Cui W, Milner-Watts C, O'Sullivan H et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur. J. Cancer 2022; 171; 44-54.
Tivey A, Church M, Rothwell D, Dive C, Cook N. Circulating tumour DNA-looking beyond the blood. Nat. Rev. Clin. Oncol. 2022; 19; 600-612.
Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 2014; 32; 579-586.
Rolfo C, Mack P, Scagliotti GV et al. Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer. J. Thorac. Oncol. 2021; 16; 1647-1662.
Li BT, Janku F, Jung B et al. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the actionable genome consortium. Ann. Oncol. 2019; 30; 597-603.
Guibert N, Pradines A, Mazieres J, Favre G. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. Eur. Respir. Rev. 2020; 29; 190052.
Aggarwal C, Rolfo CD, Oxnard GR, Gray JE, Sholl LM, Gandara DR. Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. Nat. Rev. Clin. Oncol. 2020; 18; 56-62.
Heitzer E, van den Broek D, Denis MG et al. Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer. ESMO Open 2022; 7; 100399.
Pascual J, Attard G, Bidard FC et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 2022; 33; 750-768.
Takeyasu Y, Yoshida T, Motoi N et al. Feasibility of next-generation sequencing (Oncomine™ DX target test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients. Jpn. J. Clin. Oncol. 2021; 51; 1114-1122.
Gagné A, Wang E, Bastien N et al. Impact of specimen characteristics on PD-L1 testing in non-small cell lung cancer: validation of the IASLC PD-L1 testing recommendations. J. Thorac. Oncol. 2019; 14; 2062-2070.
Roche. [Internet] cobas® EGFR Mutation Test v2 [package insert] [cited July 7 2022]. Available from https://diagnostics.roche.com/.
Roche. [Internet] cobas® KRAS Mutation Test [package insert] [cited July 7 2022]. Available from https://diagnostics.roche.com/.
Amemiya K, Hirotsu Y, Nagakubo Y et al. Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer. Cancer Cytopathol. 2021; 129; 729-738.
Rolfo C, Manca P, Salgado R et al. Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer. ESMO Open 2018; 3; e000398.
Suh JH, Johnson A, Albacker L et al. Comprehensive genomic profiling facilitates implementation of the National Comprehensive Cancer Network Guidelines for lung cancer biomarker testing and identifies patients who may benefit from enrollment in mechanism-driven clinical trials. Oncologist 2016; 21; 684-691.